Erlotinib-induced Acneiform Rash Not Affecting Previously Irradiated Skin

Erucción Acneiforme Onducida por Erlotinib que Respetá el Área de Piel Previamente Irradiada

To the Editor:

Erlotinib is a tyrosine kinase inhibitor that acts by blocking the activity of the epidermal growth factor receptor (EGFR). This receptor is frequently overexpressed and mutated in many solid tumors, and is also abundant in the basal cells of the epidermis and in follicular keratinocytes, where it contributes to the differentiation and development of the hair follicle. Currently, erlotinib is indicated for the treatment of non-small cell lung cancer and pancreatic cancer, and is being investigated as a treatment option in cancers of the head and neck, ovary and kidney. Adverse skin reactions are the most frequent adverse effect of erlotinib. The pathogenesis of acneiform reactions that have spared irradiated skin, is a local reduction in the drug effect, due to either a decrease in the uptake of the drug by the skin, or a decreased pharmacologic effect due to a decrease in the number of EGFR expressing keratinocytes. Our case does not support this hypothesis, because pilosebaceous units were observed in the irradiated area.

The effects of radiation therapy vary according to the time since the treatment. During the first 3 weeks, radiation therapy leads to increases in basal layer proliferation and in the mitotic index. Several weeks after irradiation there is a local reduction in the drug effect, due to either a progressive loss of endothelial cells and the drug not reaching the irradiated area, or to a modification of epidermal sensitivity to EGFR inhibitors. There are reports of cases in which following the concomitant administration of an EGFR inhibitor during the course of radiation therapy with erlotinib (150 mg/d orally). Ten days after beginning drug therapy, numerous papules and confluent pustules appeared that were distributed on the face, trunk, and arms. Surprisingly, the rash spared 2 rectangular areas located on the anterior and posterior area of the neck and upper trunk, which had been included within the fields of radiation therapy (Figure 1). Biopsy of the skin affected by the rash demonstrated acute superficial folliculitis (Figure 2), whereas biopsy of the irradiated area only demonstrated some discrete perivascular infiltrates formed predominantly of lymphocytes. The patient was treated with oral doxycycline (100 mg/d). After 2 months, the oncologists decided to suspend the treatment with erlotinib due to inefficacy. The skin lesions gradually improved and had completely disappeared by 3 months.

In the case described, the type of lesions and the time of onset were similar to those found in most patients who suffer this adverse skin reaction caused by treatment with erlotinib. The main interest of the case presented is that the lesions spared previously irradiated skin. To date, very few cases have been reported of EGFR-inhibitor-associated acneiform reactions that have spared irradiated skin, and erlotinib was involved only in 3 of those cases.

The pathogenesis of this event is unknown. One theory suggests that radiation therapy causes atrophy of the sebaceous glands, which would explain the lack of lesions in the irradiated area. Our case does not support this hypothesis, because pilosebaceous units were observed in the irradiated area.

The pathogenesis of this event is unknown. One theory suggests that radiation therapy causes atrophy of the sebaceous glands, which would explain the lack of lesions in the irradiated area. Our case does not support this hypothesis, because pilosebaceous units were observed in the irradiated area.

The effects of radiation therapy vary according to the time since the treatment. During the first 3 weeks, radiation therapy leads to increases in basal layer proliferation and in the mitotic index. Several weeks after irradiation there is a local reduction in the drug effect, due to either a progressive loss of endothelial cells and the drug not reaching the irradiated area, or to a modification of epidermal sensitivity to EGFR inhibitors. There are reports of cases in which following the concomitant administration of an EGFR inhibitor during the course of radiation therapy...


P. Hernández-Bel, a,b M. J. Gómez-Maestra, a Torrijos-Aguilar, b J. López, a J. J. Dilata, a and V. Alegre a

aServicio de Dermatología, Consorcio Hospital General Universitario de Valencia, Valencia, Spain bServicio de Oftalmología, Hospital Universitario La Fe, Valencia, Spain cServicio de Dermatología, Hospital Provincial de Castellón, Castellón, Spain

*Corresponding author.
E-mail address: pablohernandezbel@hotmail.com (P.Hernández-Bel).
or immediately afterwards, the acneiform rash was limited to or more severe in the previously irradiated skin when an EGFR inhibitor was administered during the course of radiation therapy or immediately afterwards. Variations in the interval between irradiation and the administration of EGFR inhibitors probably explain the absence or increased severity of the acneiform rash in the irradiated skin.

**Conflict of Interests**

The authors declare no conflict of interests.

**References**

5. Sanz A, del Valle ML. A man whose scapula was spared a drug-associated rash. CMAJ. 2005;172:745.


**Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, Spain**

*Corresponding author.

**E-mail address:** c.eguren@hotmail.com (C. Eguren)